Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Terminated 2Completed 2Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3Genitourinary 2Other hematologic neoplasm 1Head & Neck 1CNS 1Breast 1

Conditions

Upper Tract Urothelial Carcinomas 1Renal Pelvis and Ureter Urothelial Carcinoma 1

Interventions

Docetaxel 69pembrolizumab 48Prednisone 43Nivolumab 40enzalutamide 38Gemcitabine 37Sunitinib 36Cyclophosphamide 29Radiotherapy 26Magnetic Resonance Spectroscopy 26Leuprolide 25Abiraterone Acetate 25Sorafenib 23Everolimus 23Cisplatin 23bicalutamide 19atezolizumab 18Carboplatin 18Bevacizumab 18avelumab 17Radiosurgery 17Goserelin 17Interleukin-2 16abiraterone 15fludarabine 14Doxorubicin 14olaparib 13durvalumab 13cabozantinib 13acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × infigratinib × Genitourinary × Clear all
NCT04228042 2025-01-01

Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer

M.D. Anderson Cancer Center

Phase 1/2 Terminated
15 enrolled 10 charts
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

NCT04197986 2024-03-13

PROOF302

QED Therapeutics, a BridgeBio company

Phase 3 Terminated
39 enrolled 31 charts
Genitourinary

Upper Tract Urothelial Carcinomas

Data powered by HemOnc (CC BY 4.0) Colophon âš¡